ReviewVaccines2021
A Narrative Review of COVID-19 Vaccines.
Review in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Trial
- Predicting COVID-19 vaccination timing by integrating the theory of planned behavior and the diffusion of innovations: a cross-sectional survey in Macao, China.Journal of thoracic disease · 2025Article
- Visual analysis on ferroptosis and its cross-talk to coronavirus disease 2019 (COVID-19).Heliyon · 2024Article
- COVID-19 vaccines: current and future challenges.Frontiers in pharmacology · 2024Review
- Waning of SARS-CoV-2 Vaccine Effectiveness in COPD Patients: Lessons from the Delta Variant.Vaccines · 2023Article
- SARS-CoV-2 Vaccine Effectiveness in Hospitalized Patients: A Multicenter Test-Negative Case-Control Study.Vaccines · 2023Article
- How can COVID-19 vaccines benefit people? A study based on the theory of the commons.Human vaccines & immunotherapeutics · 2023Article
- Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SYS6006, as a fourth-dose booster following three doses of inactivated vaccines in healthy adults: an open-labeled Phase 1 trial.Life metabolism · 2023Article
- A Review of Inactivated COVID-19 Vaccine Development in China: Focusing on Safety and Efficacy in Special Populations.Vaccines · 2023Review
- Article
- Trusted information sources in the early months of the COVID-19 pandemic predict vaccination uptake over one year later.Vaccine · 2023Article
- Exploring the experience of developing COVID-19 vaccines in Iran.Clinical and experimental vaccine research · 2023Review
- COVID-19 Vaccine: Predicting Vaccine Types and Assessing Mortality Risk Through Ensemble Learning Algorithms.F1000Research · 2023Article
- What we talk about when we talk about COVID-19 vaccination campaign impact: a narrative review.Frontiers in public health · 2023Review
- Article
- Immunogenicity and Efficacy of Monovalent and Bivalent Formulations of a Virus-Like Particle Vaccine against SARS-CoV-2.Vaccines · 2022Article
- Increased risk of myocarditis and pericarditis and reduced likelihood of severe clinical outcomes associated with COVID-19 vaccination: a cohort study in Lombardy, Italy.BMC infectious diseases · 2022Article
- Systematic Down-Selection of Repurposed Drug Candidates for COVID-19.International journal of molecular sciences · 2022Article
- Recombinant vaccines in 2022: a perspective from the cell factory.Microbial cell factories · 2022Review
- Planning and Organization of the COVID-19 Vaccination Campaign: An Overview of Eight European Countries.Vaccines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic has shaken the world since early 2020 and its health, social, economic, and societal negative impacts at the global scale have been catastrophic. Since the early days of the pandemic, development of safe and effective vaccines was judged to be the best possible tool to minimize the effects of this pandemic. Drastic public health measures were put into place to stop the spread of the virus, with the hope that vaccines would be available soon. Thanks to the extraordinary commitments of many organizations and individuals from around the globe and the collaborative effort of many international scientists, vaccines against COVID-19 received regulatory approval for emergency human use in many jurisdictions in less than a year after the identification of the viral sequence. Several of these vaccines have been in use for some time; however, the pandemic is still ongoing and likely to persist for the foreseeable future. This is due to many reasons including reduced compliance with public health restrictions, limited vaccine manufacturing/distribution capacity, high rates of vaccine hesitancy, and the emergence of new variants with the capacity to spread more easily and to evade current vaccines. Here we discuss the discovery and availability of COVID-19 vaccines and evolving issues around mass vaccination programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.